US Treasury draft COINS rules could sharply limit China biotech partnerships
US Treasury released a draft set of regulations known as the COINS rule that targets cross-border biotech transactions. The proposal would bar certain US-China deals and tighten oversight of collaborations.
Experts say the draft could sharply limit joint research and investment between American and Chinese biotech firms, potentially disrupting existing pipelines.
Industry observers warn the rules may deter future partnerships and raise compliance costs, prompting a heated debate in Washington and among investors.
The discussion highlights uncertainty for companies that rely on China collaborations and may shape the strategic direction of the sector.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Draft COINS rules could threaten broad China collaborations”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that